Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 권지원 | - |
dc.date.accessioned | 2019-12-09T07:58:11Z | - |
dc.date.available | 2019-12-09T07:58:11Z | - |
dc.date.issued | 2018-09 | - |
dc.identifier.citation | BMC OPHTHALMOLOGY, v. 18, Article no. 237 | en_US |
dc.identifier.issn | 1471-2415 | - |
dc.identifier.uri | https://bmcophthalmol.biomedcentral.com/articles/10.1186/s12886-018-0910-3 | - |
dc.identifier.uri | https://repository.hanyang.ac.kr/handle/20.500.11754/120174 | - |
dc.description.abstract | Background: To investigate therapeutic effects of topical diquafosol tetrasodium 3% ophthalmic solution in patients with short tear film break-up time (TFBUT)-type dry eye (DE).Methods: The prospective study was performed in 70 eyes of 70 patients with short TFBUT-type DE. Diagnosis of short TFBUT-type DE was made based on the presence of DE symptoms, TFBUT value <= 5 s, corneoconjunctival staining score <= 2 ( on a scale of 0 to 4), and Schirmer I value > 5 mm. Patients with systemic immunologic disorders or ocular graft-versus-host disease were excluded. Before and after instillation of 3% diquafosol ophthalmic solution six times per day for 4 weeks, subjective DE symptoms, TFBUT, corneoconjunctival staining score, and Schirmer I value were examined and compared. Also, demographic factors were compared between patients who showed improvement in each DE parameter by treatment and those who did not.Results: Four-week treatment with 3% diquafosol ophthalmic solution significantly improved DE symptoms (p < 0.0001), increased TFBUT (p < 0.0001), and reduced corneoconjunctival staining scores (p < 0.0001). Schirmer I values were not changed by treatment. The age of patients who showed improvement in subjective DE symptoms after treatment was significantly lower than that of patients who did not (53.4 +/- 27.5 vs. 63.3 +/- 13.9 years, p = 0.012). Ocular side effects developed in 3 patients (4.3%), including conjunctival chemosis (n = 1) and persistent stinging sensation (n = 2).Conclusions: Diquafosol tetrasodium 3% ophthalmic solution is effective in improving subjective symptoms and tear film stability in short TFBUT-type DE patients. | en_US |
dc.description.sponsorship | This study was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT and future Planning (2018R1A2B2004108). | en_US |
dc.language.iso | en_US | en_US |
dc.publisher | BMC | en_US |
dc.subject | Diquafosol tetrasodium 3% | en_US |
dc.subject | Dry eye disease | en_US |
dc.subject | Short tear film break-up time-type dry eye | en_US |
dc.title | Therapeutic effects of 3% diquafosol ophthalmic solution in patients with short tear film break-up time-type dry eye disease | en_US |
dc.type | Article | en_US |
dc.relation.volume | 18 | - |
dc.identifier.doi | 10.1186/s12886-018-0910-3 | - |
dc.relation.page | 237-242 | - |
dc.relation.journal | BMC OPHTHALMOLOGY | - |
dc.contributor.googleauthor | Mun, Yongseok | - |
dc.contributor.googleauthor | Kwon, Ji-Won | - |
dc.contributor.googleauthor | Oh, Joo Youn | - |
dc.relation.code | 2018004328 | - |
dc.sector.campus | S | - |
dc.sector.daehak | COLLEGE OF MEDICINE[S] | - |
dc.sector.department | DEPARTMENT OF MEDICINE | - |
dc.identifier.pid | wind0515 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.